Literature DB >> 15674951

Chinese medical herbs for chemotherapy side effects in colorectal cancer patients.

W Taixiang1, A J Munro, L Guanjian.   

Abstract

BACKGROUND: Side effects, including nausea and vomiting, sore mouth , diarrhoea, hepatotoxicity, myelosuppression, and immunosuppression , are commonly encountered in patients with colorectal cancer who are treated with chemotherapy. A variety of Chinese herbal medicines have been used for managing these adverse effects.
OBJECTIVES: To assess the effect of herbal medicines plus chemotherapy, compared with chemotherapy alone, on the side effects of chemotherapy on the quality of life, and on adverse events in patients with colorectal cancer. SEARCH STRATEGY: We searched the Cochrane Library, MEDLINE, EMBASE, CBM, and handsearched the relevant Chinese journals. SELECTION CRITERIA: Randomised trials comparing either chemotherapy only or chemotherapy plus anti-emetics (tropisetron, sulpiride etc) with chemotherapy plus Chinese herbs. DATA COLLECTION AND ANALYSIS: Trial quality was assessed independently by two reviewers. Data were extracted by one reviewer and checked by the second reviewer. Since the four included studies differed significantly in design, we could only perform limited meta-analyses. We have therefore presented the majority of the data in narrative form. MAIN
RESULTS: We included four relevant trials. All of them were of low quality. All of studies used a decoction containing Huangqi compounds as the intervention with chemotherapy. The intervention groups of three studies were compared to a chemotherapy alone control group, the fourth study compared the decoction of Huangqi compounds with two other Chinese herbal interventions. None of the studies reported on primary outcome using Common Toxicity Criteria (CTC). There was a significant reduction in the proportion of patients who experienced nausea & vomiting when decoctions of Huangqi compounds were given in addition to chemotherapy. There was also a decrease in the rate of leucopenia (WBC <3 x 10(9) per L). Huangqi compounds were also associated with increases in the proportions of T-lymphocyte subsets: CD3; CD4 and CD8. Huangqi decoctions had no significant effects on Immunoglobulins G, A or M. AUTHORS'
CONCLUSIONS: Despite the included studies being of low quality, the results suggest that decoctions of Huangqi compounds may stimulate immunocompetent cells and decrease side effects in patients treated with chemotherapy. Due to the methodological limitations of the studies, there is no robust demonstration of benefit. We found no evidence of harm arising from the use of Chinese herbs. We need high quality randomised controlled studies investigating the effects of decoctions of Chinese herbs, particularly Astragalus spp.(as in Huangqi), upon chemotherapy-related side effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15674951      PMCID: PMC8829831          DOI: 10.1002/14651858.CD004540.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  39 in total

1.  [Clinical study on effect of shenqi fuzheng injection combined with chemotherapy in treating gastric cancer].

Authors:  K Zhou; J Wang; B Liu
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  1999-01

2.  Effects of shenmai injection on expression of TNF-alpha mRNA in peritoneal macrophages of scald mice.

Authors:  Runtian Wang; Chao Gao; Dianwu Liu
Journal:  Chin Med J (Engl)       Date:  2002-02       Impact factor: 2.628

3.  Colorectal cancer screening: clinical guidelines and rationale.

Authors:  S J Winawer; R H Fletcher; L Miller; F Godlee; M H Stolar; C D Mulrow; S H Woolf; S N Glick; T G Ganiats; J H Bond; L Rosen; J G Zapka; S J Olsen; F M Giardiello; J E Sisk; R Van Antwerp; C Brown-Davis; D A Marciniak; R J Mayer
Journal:  Gastroenterology       Date:  1997-02       Impact factor: 22.682

4.  Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States.

Authors:  W Haenszel; M Kurihara
Journal:  J Natl Cancer Inst       Date:  1968-01       Impact factor: 13.506

5.  [Clinical study on treatment of advanced non-small cell lung cancer with Chinese herbal medicine combined with synchronous radio- and chemotherapy].

Authors:  X Liu; B Wang; X Fu
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2000-06

Review 6.  Surgery for colorectal cancer in elderly patients: a systematic review. Colorectal Cancer Collaborative Group.

Authors: 
Journal:  Lancet       Date:  2000-09-16       Impact factor: 79.321

7.  Cancer mortality risk among Japanese in the United States.

Authors:  F B Locke; H King
Journal:  J Natl Cancer Inst       Date:  1980-11       Impact factor: 13.506

8.  Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy.

Authors:  C G Moertel; T R Fleming; J S Macdonald; D G Haller; J A Laurie
Journal:  J Clin Oncol       Date:  1993-12       Impact factor: 44.544

Review 9.  Treatment of colorectal cancer. Current guidelines and future prospects for drug therapy.

Authors:  R Labianca; M A Pessi; G Zamparelli
Journal:  Drugs       Date:  1997-04       Impact factor: 11.431

10.  Oral administration of a Kampo (Japanese herbal) medicine Juzen-taiho-to inhibits liver metastasis of colon 26-L5 carcinoma cells.

Authors:  Y Ohnishi; H Fujii; Y Hayakawa; R Sakukawa; T Yamaura; T Sakamoto; K Tsukada; M Fujimaki; S Nunome; Y Komatsu; I Saiki
Journal:  Jpn J Cancer Res       Date:  1998-02
View more
  30 in total

Review 1.  Evidence from the Cochrane Collaboration for Traditional Chinese Medicine therapies.

Authors:  Eric Manheimer; Susan Wieland; Elizabeth Kimbrough; Ker Cheng; Brian M Berman
Journal:  J Altern Complement Med       Date:  2009-09       Impact factor: 2.579

2.  Survivorship care plans for people with colorectal cancer: do they reflect the research evidence?

Authors:  V D'Souza; H Daudt; A Kazanjian
Journal:  Curr Oncol       Date:  2016-10-25       Impact factor: 3.677

3.  Association Between Use of Traditional Chinese Medicine Herbal Therapy and Survival Outcomes in Patients With Stage II and III Colorectal Cancer: A Multicenter Prospective Cohort Study.

Authors:  Yun Xu; Jun J Mao; Lingyun Sun; Lin Yang; Jie Li; Yingxu Hao; Huashan Li; Wei Hou; Yuping Chu; Yu Bai; Xiaoqiang Jia; Jinwan Wang; Lin Shen; Ying Zhang; Jianbin Wang; Jianping Liu; Yufei Yang
Journal:  J Natl Cancer Inst Monogr       Date:  2017-11-01

4.  The Western model of integrative oncology: the contribution of Chinese medicine.

Authors:  Gustav J Dobos; Barbara Kirschbaum; Kyung-Eun Choi
Journal:  Chin J Integr Med       Date:  2012-08-31       Impact factor: 1.978

5.  A prospective, controlled study of the botanical compound mixture LCS101 for chemotherapy-induced hematological complications in breast cancer.

Authors:  Neora Yaal-Hahoshen; Yair Maimon; Nava Siegelmann-Danieli; Shahar Lev-Ari; Ilan G Ron; Fani Sperber; Noah Samuels; Jacob Shoham; Ofer Merimsky
Journal:  Oncologist       Date:  2011-06-28

Review 6.  The model of Western integrative medicine: the role of Chinese medicine.

Authors:  Gustav Dobos; Iven Tao
Journal:  Chin J Integr Med       Date:  2011-01-22       Impact factor: 1.978

Review 7.  [Nutrition, lifestyle, physical activity, and supportive care during chemotherapeutic treatment].

Authors:  G Lümmen; T Jäger; F Sommer; T Ebert; B Schmitz-Draeger
Journal:  Urologe A       Date:  2006-05       Impact factor: 0.639

8.  Induction of apoptosis and G2 /M cell cycle arrest by Scrophularia striata in a human leukaemia cell line.

Authors:  A Azadmehr; R Hajiaghaee; M Mazandarani
Journal:  Cell Prolif       Date:  2013-12       Impact factor: 6.831

9.  Apoptosis Cell Death Effect of Scrophularia Variegata on Breast Cancer Cells via Mitochondrial Intrinsic Pathway.

Authors:  Abbas Azadmehr; Reza Hajiaghaee; Behzad Baradaran; Hashem Haghdoost-Yazdi
Journal:  Adv Pharm Bull       Date:  2015-09-19

10.  Evaluating the quality of randomized controlled trials that examine the efficacy of natural health products: a systematic review of critical appraisal instruments.

Authors:  Anne Marie Whelan; Tannis M Jurgens; Lindsay Lord
Journal:  Evid Based Complement Alternat Med       Date:  2008-01-18       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.